(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 23.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Mirum Pharmaceuticals's revenue in 2026 is $569,609,000.On average, 14 Wall Street analysts forecast MIRM's revenue for 2026 to be $42,000,820,096, with the lowest MIRM revenue forecast at $39,980,512,046, and the highest MIRM revenue forecast at $43,732,686,943. On average, 14 Wall Street analysts forecast MIRM's revenue for 2027 to be $50,706,500,063, with the lowest MIRM revenue forecast at $42,572,824,006, and the highest MIRM revenue forecast at $57,409,556,535.
In 2028, MIRM is forecast to generate $66,164,631,295 in revenue, with the lowest revenue forecast at $56,439,955,025 and the highest revenue forecast at $79,458,538,781.